Difference between revisions of "Radiotherapy toxicity management"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "<big>" to "") |
Warner-admin (talk | contribs) m (Text replacement - "</big>" to "") |
||
| Line 4: | Line 4: | ||
</div> | </div> | ||
{{#lst:Editorial board transclusions|rt_tox}} | {{#lst:Editorial board transclusions|rt_tox}} | ||
| − | '''The purpose of this page is to address the management of toxicity from radiation therapy.''' | + | '''The purpose of this page is to address the management of toxicity from radiation therapy.''' |
To be created! | To be created! | ||
Latest revision as of 00:27, 4 July 2024
| Focus editor | Associate editor | ||
|---|---|---|---|
 |
Michael K. Rooney, MD MD Anderson Cancer Center Houston, TX, USA |
 |
Danielle S. Bitterman, MD Dana-Farber Cancer Institute Boston, MA, USA |
The purpose of this page is to address the management of toxicity from radiation therapy.
To be created!
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
ASCO
- 2008: Hensley et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants PubMed
- 2002: Schuchter et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology PubMed
- 1999: Hensley et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants PubMed